Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
America needs to be prepared for the next health crisis WASHINGTON — The Coalition for a Prosperous America (CPA) urged the U.S. Trade Representative (USTR)
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
U.S. pharmaceutical imports have skyrocketed in the last ten years, with imports from China, India and Mexico leading the surge.
